In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be offered as "incorporate-on" therapy. In Section C, https://jacky211mxh4.wikikarts.com/user